Feedback (FDBK)

Sector:

Health Care

Index:

FTSE AIM All-Share

 14.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 64.00p
  • 52 Week Low: 13.75p
  • Currency: UK Pounds
  • Shares Issued: 43.81m
  • Volume: 12,500
  • Market Cap: £6.35m
  • RiskGrade: 267
  • Beta: 0.00

Bleepa drives first-half growth for Feedback

By Josh White

Date: Tuesday 25 Feb 2025

LONDON (ShareCast) - (Sharecast News) - Feedback reported a 3% increase in revenue to £0.45m for the six months ended 30 November on Tuesday, with its flagship product, Bleepa, contributing 90% of that figure.
The AIM-traded firm said sales rose by 43% to £0.59m, while EBITDA losses narrowed to £1.43m from £1.68m a year earlier.

It also raised £6.1m through an upscaled placing and subscription, with net proceeds reaching £5.6m.

Cash reserves stood at £7.26m at the period's end, up from £3.88m last May.

Operational progress included a £0.5m contract with Queen Victoria Hospital NHS Foundation Trust for digital infrastructure, and further funding to extend a community diagnostic centre pilot at Northern Care Alliance NHS Foundation Trust.

Feedback said it had also started integrating Bleepa with key NHS referral systems to enhance scalability and broadened its global reach through a collaboration with Vertex In Healthcare.

The company signed a memorandum of understanding with an NHS Trust and a primary care solutions partner to trial a 'neighbourhood diagnostics solution', aligning with the government's vision for a digital-first, community-centric healthcare system.

Post-period developments included the launch of two revenue-generating projects in India - a pilot with a major Asian hospital group and a tuberculosis screening programme with HEAL Foundation.

Feedback also successfully completed Bleepa integrations with two NHS referral systems and established an external affairs department to align with the UK government's increased focus on elective care.

Discussions with partners were continuing as the company looked to expand its role within the NHS.

"We remain extremely excited by the wider market opportunity," said chief executive officer Dr Tom Oakley.

"We have a product base aligned with increased focus on digitisation and patient-centric models while our relationships and proven technology ensure that Feedback is positioned to scale up delivery.

"Market drivers and the top-down approach - led by government focus on reform, underpin our confidence.

"We have a growing pipeline of opportunities and routes to market, which we believe will drive meaningful revenues as we focus on conversion."

At 1315 GMT, shares in Feedback were down 3.84% at 17.55p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Feedback Market Data

Currency UK Pounds
Share Price 14.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 64.00p
52 Week Low 13.75p
Volume 12,500
Shares Issued 43.81m
Market Cap £6.35m
Beta 0.00
RiskGrade 267

Feedback Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
0.21% above the market average0.21% above the market average0.21% above the market average0.21% above the market average0.21% above the market average
63.64% above the sector average63.64% above the sector average63.64% above the sector average63.64% above the sector average63.64% above the sector average
Price Trend
90.95% below the market average90.95% below the market average90.95% below the market average90.95% below the market average90.95% below the market average
65.71% below the sector average65.71% below the sector average65.71% below the sector average65.71% below the sector average65.71% below the sector average
Income Not Available
Growth
48.47% above the market average48.47% above the market average48.47% above the market average48.47% above the market average48.47% above the market average
48.57% above the sector average48.57% above the sector average48.57% above the sector average48.57% above the sector average48.57% above the sector average

What The Brokers Say

Strong Buy 1
Buy 1
Neutral 0
Sell 0
Strong Sell 0
Total 2
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Feedback Dividends

No dividends found

Trades for 21-Jul-2025

Time Volume / Share Price
08:44 12,500 @ 14.25p

Feedback Key Personnel

CEO Tom Oakley
CFO Anesh Patel

Top of Page